Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2017–2021

GLIOTRAIN · Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2017-09-01 → 2021-08-31
Финансиране от ЕС
3 836 772 €
Участници
23
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Глиобластомата, най-агресивният вид тумор в мозъка, се анализира чрез генетични мутации и механизми на устойчивост към лекарствата. Това помага за търсенето на нови стратегии за лечение и по-точна медицина при пациенти с този вид рак.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Worldwide there are c. 240,000 cases of brain and nervous system tumours per year. Glioblastoma (GBM) is the most frequent and aggressive. Despite significant efforts clinicians remain unable to offer curative therapy. 85% of patients die within 2 years despite aggressive treatment (surgical resection + radio-chemotherapy + temozolomide). Diverse elements underpin the intractability of GBM including its infiltrative nature, rapid proliferative rate, treatment resistance, the blood brain barrier impeding access of drugs, activation of multiple signal transduction pathways/specific gene mutations and intra/inter-tumoural heterogeneity. New treatment options and effective precision medicine therapies are urgently required. The objective of GLIOTRAIN was to exploit the intractability of GBM to address European applied biomedical research training needs, to identify novel therapeutic strategies for application in GBM and unravel disease resistance mechanisms.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз